Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized multicenter phase II trial to evaluate the effectiveness of selective neoadjuvant treatment according to immunohistochemical subtype for HER2 [human epidermal growth factor receptor-2] negative breast cancer patients.

Next Previous
X
Search
Trial Profile

A randomized multicenter phase II trial to evaluate the effectiveness of selective neoadjuvant treatment according to immunohistochemical subtype for HER2 [human epidermal growth factor receptor-2] negative breast cancer patients.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exemestane (Primary) ; Goserelin (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 05 Jun 2018 Results of a genomic analysis from NCT00432172 and NCT00841828 studies presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 21 Nov 2012 Planned end date changed from 1 Dec 2011 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 06 Jun 2012 Results published in Annals of Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top